Sugi Predict

Sugi Predict / Compounds / SCHEMBL15065573

SCHEMBL15065573

SCHEMBL15065573

CC[CH]NCc1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ ALDH1A1 P00352 6/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ PKM P14618 2/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ RECQL P46063 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CTSL P07711 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ LTA4H P09960 1/20 0.50
▸ TP53 P04637 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13373199 0.79 CYP1A2 (0.58) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL26780009 0.78 CYP1A2 (0.62) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL3160679 0.78 CYP1A2 (0.62) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL348709 0.78 CYP1A2 (0.68) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL4960529 0.77 LMNA (0.44) ALDH1A1HTTLMNAKDM4EGAA
SCHEMBL1527046 0.77 ADH1B (0.56) ALDH1A1KMT2ASMN1; SMN2TP53POLB
SCHEMBL6645275 0.76 CYP1A2 (0.65) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL1037867 0.76 CYP1A2 (0.77) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL2313650 0.75 — —
SCHEMBL46656 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111182898-B Methods for treating huntington's disease PTC医疗公司 2024-04-16 — — CN disclosed
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 — — US disclosed
US-20230310651-A1 METHODS FOR MODULATING RNA SPLICING PTC THERAPEUTICS, INC. (US) 2023-10-05 — — US disclosed
EP-4249472-A2 METHODS FOR MODULATING RNA SPLICING PTC Therapeutics, Inc. (US) 2023-09-27 — — EP disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-20230272367-A1 METHODS FOR MODULATING RNA SPLICING PTC THERAPEUTICS, INC. (US) 2023-08-31 — — US disclosed
EP-3644996-B1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2023-07-26 — — EP disclosed
US-11702646-B2 Methods for modulating RNA splicing PTC THERAPEUTICS, INC. (US) 2023-07-18 — — US disclosed
EP-3310169-B1 METHODS FOR MODULATING RNA SPLICING PTC THERAPEUTICS INC (US) 2023-05-17 — — EP disclosed
US-11602567-B2 Methods for modulating RNA splicing PTC THERAPEUTICS, INC. (US) 2023-03-14 — — US disclosed
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2015-01-01 — — US disclosed
EP-2812004-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-12-17 — — EP disclosed
EP-2809322-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-12-10 — — EP disclosed
CN-104203239-A Compounds for treating spinal muscular atrophy PTC THERAPEUTICS INC 2014-12-10 — — CN disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 — — EP disclosed
WO-2013142236-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-09-26 — — WO disclosed
WO-2013130689-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-09-06 — — WO disclosed
WO-2013119916-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-15 — — WO disclosed
WO-2013112788-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-01 — — WO disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CYP1A2 4324/4885CYP2D6 4593/4885ALDH1A1 1088/4885
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CYP1A2 4663/4885CYP2D6 4793/4885ALDH1A1 1461/4885
US-20230272367-A1 METHODS FOR MODULATING RNA SPLICING RBM17, SNRPE, HNRNPM CYP1A2 4151/4885CYP2D6 4366/4885ALDH1A1 3830/4885
US-11702646-B2 Methods for modulating RNA splicing RBM17, SNRPE, HNRNPM CYP1A2 4151/4885CYP2D6 4366/4885ALDH1A1 3830/4885
US-11602567-B2 Methods for modulating RNA splicing RBM17, SNRPE, RBM3 CYP1A2 4330/4885CYP2D6 4512/4885ALDH1A1 3799/4885
US-20230310651-A1 METHODS FOR MODULATING RNA SPLICING RBM17, SNRPE, RBM3 CYP1A2 4330/4885CYP2D6 4512/4885ALDH1A1 3799/4885
US-11753407-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 CYP1A2 4094/4885CYP2D6 3271/4885ALDH1A1 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.